Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drugs in development for hepatitis B.

Maria Buti1, Rafael Esteban

  • 1Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain. mbuti@vhebron.net

Drugs
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimization of a mobile application for the management of hepatitis D based on patient experience: an observational study in a hepatology cohort.

Gastroenterologia y hepatologia·2026
Same author

No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence-Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same author

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

The New England journal of medicine·2026
Same author

Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia.

Scientific reports·2026
Same author

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.

JHEP reports : innovation in hepatology·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Newer drugs improve chronic hepatitis B (CHB) management by inhibiting hepatitis B virus (HBV) DNA replication. Sustained off-therapy suppression remains rare, driving research into novel antiviral and immunomodulatory agents for long-term treatment.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B (CHB) management has advanced with new drugs like lamivudine and adefovir dipivoxil, alongside interferon-alpha therapy.
  • While current treatments reduce hepatitis B virus (HBV) DNA replication, sustained off-therapy suppression is infrequent, especially in HBeAg-negative patients.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for chronic hepatitis B.
  • To evaluate the efficacy and limitations of new antiviral and immunomodulatory agents in CHB management.

Main Methods:

  • Review of recent clinical studies and drug evaluations for CHB treatment.
  • Analysis of antiviral and immunomodulatory agents, including pegylated interferon-alpha, entecavir, tenofovir disoproxil fumarate, and telbivudine.

Related Experiment Videos

  • Assessment of combination therapy approaches and their impact on viral resistance.

    • Main Results:

    • Pegylated interferon-alpha shows promise for HBeAg-positive CHB, particularly with HBV genotypes A and B.
    • Newer antivirals (entecavir, tenofovir, telbivudine) offer potent viral inhibition but face resistance challenges.
    • Combination therapies show limited short-term virological improvement but may reduce resistance during prolonged treatment.

    Conclusions:

    • Long-term use of potent antiviral drugs with favorable safety and low resistance profiles is the likely future for CHB management.
    • Addressing sustained off-therapy suppression and managing drug resistance are key challenges in optimizing CHB treatment.
    • Further research into novel agents and combination therapies is essential for improving long-term outcomes in CHB patients.